Latest news with #GP2
India.com
16-07-2025
- Automotive
- India.com
Indian Racing Festival 2025 Flags Off with Historic Driver Draft in Mumbai
The Indian Racing Festival (IRF) 2025 marked a landmark moment for Indian motorsport with the first-ever official Driver Draft of the Indian Racing League (IRL), held at Taj Lands End in Mumbai. This event brought together franchise owners, top league officials, and media, laying the foundation for an exhilarating season ahead. The draft introduced a transparent, structured approach to team building—selecting 24 drivers across six franchises. Each team drafted an international ace, an emerging talent, a domestic star, and a female racer, showcasing IRF's commitment to inclusivity and competitive excellence. Fans can look forward to seasoned racers like Le Mans winner Neel Jani (Kichcha's Kings Bengaluru), two-time IRL champion Raoul Hyman (Goa Aces), and GP2 veteran Jon Lancaster (Hyderabad Blackbirds). Rising Indian talents such as Ruhaan Alva, Sai Sanjay, Sohil Shah, and Akshay Bohra bring fresh energy, while accomplished women drivers like Fabienne Wohlwend and Gabriela Jilkova ensure diverse representation on the grid. The draft was followed by team announcements from celebrity owners—Arjun Kapoor, Naga Chaitanya, John Abraham, Sourav Ganguly, Sudeep Kichcha, and Keerthivasan—who shared their excitement and strategic visions. Akhilesh Reddy, Chairman & MD of Racing Promotions Pvt. Ltd. (RPPL), stated, 'With this driver draft, we're building a sport for India, by India, with the world watching.' The IRF 2025 season kicks off in August, spanning premier circuits and vibrant street tracks across India. As these franchises head into the championship with balanced, star-studded rosters, Indian motorsport stands poised for a thrilling new chapter.
Time of India
09-07-2025
- Business
- Time of India
Red Bull fires Christian Horner: You won't believe how much he and Geri Halliwell are really worth
Why did Red Bull finally fire Christian Horner? Live Events How much is Christian Horner actually worth? FAQs (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel After two turbulent years on and off the track, Christian Horner has been officially fired by Red Bull Racing . However, with a fortune in the bank and pop icon Geri Halliwell by his side, the couple isn't exactly Horner has been fired following a disappointing 2025 Formula One season and ongoing controversy. He leaves Red Bull after two decades with a massive effect from today, Wednesday, July 9, 2025, Red Bull has relieved Christian Horner of his operational responsibilities and named Laurent Mekies as Red Bull Racing's this choice comes after a difficult 18 months during which Red Bull's performance steadily a disappointing British Grand Prix in which Max Verstappen dropped from pole to fifth place, Red Bull is now in fourth place in the constructors' championship, 288 points behind McLaren. Yuki Tsunoda had a futile weekend for the team as well. Verstappen is currently only in third place, far behind Red Bull's competitors, as per a report by GB departure occurs 17 months after a female employee accused him of harassment and controlling behavior. Red Bull GmbH, the parent company of the Formula One giant, has twice cleared him of these accusations, as per a though Red Bull fired Christian Horner on Wednesday, the power couple will undoubtedly be alright for a few years to come thanks to his wealth and his wife, Geri the sport's longest-serving team principal, Horner also received the highest salary. According to Red Bull Technology LTD's financial statements, his pay increased by 11% from £8.04 million in 2022 to £8.92 million in 2023, as reported by The his salary, he had two country homes in Oxfordshire and Hertfordshire, as well as other business interests. According to the Sun, his net worth is approximately £41.4 million when all of this is taken into Horner's incredible wealth has been made public as he must now leave the team he has played for for 20 years. The combined net worth of him and his spouse is an incredible £440 million, as per a report by GB starting his career as a racer, Horner later became the team principal of Arden, a team in the GP2 series, in 1999 after that didn't work out. As a result, in 2005, he was appointed team principal at Red Bull was reportedly paid £7.7 million a year for the position. Horner is only worth about £36 million, although the couple is worth up to £440 former Spice Girls' musical career, acting roles, and her most recent endeavor, children's books, provide the majority of their they're reportedly worth around £440 million, thanks to Geri's music career and Christian's F1 Mekies, previously with Racing Bulls, is stepping in as Red Bull Racing's new CEO starting with the Belgian Grand Prix.
Miami Herald
27-06-2025
- Business
- Miami Herald
Greenwich LifeSciences Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FLORIDA / ACCESS Newswire / June 27, 2025 / RedChip Companies will air an interview with Greenwich LifeSciences, Inc. (Nasdaq:GLSI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, June 28, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interview in its entirety at: In an exclusive previously recorded interview, Snehal Patel, CEO of Greenwich LifeSciences, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the Company's mission to prevent breast cancer recurrences through GLSI-100, a novel breast cancer vaccine immunotherapy combining the HER2-derived GP2 peptide with GM-CSF. Patel highlights the promising results from a prior Phase II trial showing no metastatic recurrences in immunized patients and details the global expansion of the ongoing Phase III FLAMINGO-01 trial, now active at more than 120 sites across the U.S. and Europe. He also outlines the Company's strategy to accelerate commercialization through advanced manufacturing readiness and strong academic partnerships, positioning GLSI-100 as a potential game-changer in the HER2-positive breast cancer treatment landscape. GLSI is a client of RedChip Companies. Please read our full disclosure at About Greenwich LifeSciences, Inc. Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at About RedChip Companies RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights. To learn more about RedChip's products and services, please visit: "Discovering Tomorrow's Blue Chips Today"™ Follow RedChip on LinkedIn: Follow RedChip on Facebook: Follow RedChip on Instagram: Follow RedChip on Twitter: Follow RedChip on YouTube: Follow RedChip on Rumble: Subscribe to our Mailing List: Contact: Dave GentryRedChip Companies Inc.1-407-644-4256info@ --END-- SOURCE: RedChip Companies, Inc.
Yahoo
29-05-2025
- Business
- Yahoo
Rune Labs and Parkinson's Foundation Launch First Clinical Program to Correlate Genetic and Digital Biomarkers for Parkinson's Disease
Bringing together Rune Labs' StrivePD AI software and PD GENEration from Parkinson's Foundation, the Global Parkinson's Genetics Program (GP2) looks to accelerate therapeutic development and deployment SAN FRANCISCO, May 29, 2025--(BUSINESS WIRE)--Rune Labs, the leader in precision medicine for Parkinson's disease (PD), today announced the launch of a clinical program with Parkinson's Foundation to accelerate the discovery of genetic and digital biomarkers for PD that can be used to provide breakthroughs in diagnostics, therapy development, and clinical trial design. By mapping gene variants to real-world symptom and medication data, the study will reveal wearable-based biomarker correlations in Parkinson's patients. The study, supported through the Global Parkinson's Genetics Program (GP2), will leverage Rune Labs' StrivePD AI-driven software and PD GENEration, the flagship genetic testing and counseling initiative from the Parkinson's Foundation. The GP2 program, one of three Aligning Science Across Parkinson's (ASAP) initiative-funded programs implemented by The Michael J. Fox Foundation, aims to improve understanding of the genetic architecture of PD by integrating ancestrally diverse populations to address a large gap in scientists' knowledge about the disease. Led by Dr. Andrew B. Singleton and Dr. Cornelis Blauwendraat, GP2's partnership with the Parkinson's Foundation will further increase the ancestral diversity of global PD genetic data. Despite a growing global patient population—expected to exceed 25 million by 2050—people with Parkinson's still need advances in diagnostics and treatments, despite progress over the past two decades. The study is intended to help address this by identifying biological and digital signatures of the disease that can support earlier diagnosis, more precise patient stratification for clinical trials, and the development of better-targeted treatment strategies. Leveraging StrivePD, participants will use an iPhone and Apple Watch to track motor symptoms passively, including tremor and dyskinesia, along with self-reported activities like mood and medications, while completing remote surveys and rating scales on their health and Parkinson's symptoms. Through PD GENEration, participants will undergo genetic testing and counseling by providing a blood sample that will be used to test for clinically validated PD-related genetic variants. The study may help participants determine eligibility for genetically based clinical studies. "We believe that there is significant potential to advance Parkinson's research by combining genetic insights with real-world data derived from AI-driven platforms like StrivePD to define disease subtypes. As trials become more precise, we can leverage data from this new study to reduce the noise, match patients to the right interventions, and generate stronger evidence to support the development of much-needed personalized treatments. If you carry a gene mutation, you shouldn't be treated like every other patient. This study could move us from 'average-patient' dosing to genome-matched therapy recommendations," said Brian Pepin, CEO of Rune Labs. StrivePD closes the gap in Parkinson's care caused by infrequent specialist visits and unpredictable symptoms. Through AI-driven monitoring, the software care ecosystem combines Apple Watch data with the StrivePD app to track FDA-cleared metrics like tremor and dyskinesia, plus self-reported daily routines, to deliver real-time insights and proactive treatment guidance. By providing insights into symptoms at all hours of the day, StrivePD helps patients manage symptoms between visits, improve medication adherence, and avoid unnecessary ER trips, allowing them to take control of their disease and ease the pressure on the healthcare system. Using AI and extensive real-world patient data, StrivePD is also changing how neurological clinical trials are designed, helping improve predictive accuracy and reducing trial failures. PD GENEration from the Parkinson's Foundation is an international research initiative offering genetic testing and counseling at no cost to individuals diagnosed with PD. Since its inception in 2019, PD GENEration has enrolled over 24,000 people living with PD (PwP) across North, Central, and South America, the Caribbean, and Israel. PD GENEration's mission is to help PwP better understand their genetic link to PD and manage their PD treatment and care, contribute to the scientific understanding of PD now and into the future, and accelerate enrollment into clinical trials by empowering PwP and clinicians around the importance of genetics. "We created PD GENEration to empower those with Parkinson's and their families to know more about their disease, accelerate clinical trials [that may one day halt Parkinson's], and drive forward research into the complex genetic factors that contribute to Parkinson's severity, progression, and treatment response," said James Beck, PhD and Chief Scientific Officer of the Parkinson's Foundation. "This new study with Rune Labs brings in powerful digital insights that can help us decode Parkinson's even further and speed up the path toward more effective treatments, and one day, a cure. Together, we can make better lives for those living with PD." Initial genotype-response findings are expected in 2026, with anonymized results made available to researchers through the GP2 data repository to accelerate future studies. About Rune Labs Rune Labs is an AI-led data analytics company for precision neurology, supporting care delivery and therapy development. StrivePD is the company's care delivery ecosystem for Parkinson's disease, enabling patients and their clinicians to better manage the disease by providing access to summarized objective and subjective data to improve treatment decisions, enhance disease management and connect patients to clinical trials. For therapeutics development, biopharma and medical device companies leverage Rune's technology, network of engaged clinicians and patients, and large longitudinal real-world datasets to expedite development programs. The company has received financial backing from leading investors such as Nexus NeuroTech, Eclipse Ventures, DigiTx, TruVenturo and Moment Ventures. For more information, please visit and About Parkinson's Foundation The Parkinson's Foundation makes life better for people with Parkinson's disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson's community. Since 1957, the Parkinson's Foundation has invested more than $474 million in Parkinson's research and clinical care. Connect with us on Facebook, X, Instagram or call 1-800-4PD-INFO (1-800-473-4636). About the Global Parkinson's Genetics Program The Global Parkinson's Genetics Program (GP2) is an ambitious program focused on improving our understanding of the genetic architecture of the PD spectrum in a global context. This work will help address the most pressing needs of the global PD community, accelerating development and deployment of better PD therapies. GP2 is made up of member organizations around the world that are coming together to create a global research community. GP2 is funded by the Aligning Science Across Parkinson's (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson's Disease Research. About Parkinson's Disease Affecting an estimated one million Americans, Parkinson's disease is the second-most common neurodegenerative disease after Alzheimer's and is the 14th-leading cause of death in the U.S. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for Parkinson's and nearly 90,000 new cases are diagnosed each year in the U.S. View source version on Contacts Media Contact Consort Partners for Rune Labsrunelabs@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
Rune Labs and Parkinson's Foundation Launch First Clinical Program to Correlate Genetic and Digital Biomarkers for Parkinson's Disease
Bringing together Rune Labs' StrivePD AI software and PD GENEration from Parkinson's Foundation, the Global Parkinson's Genetics Program (GP2) looks to accelerate therapeutic development and deployment SAN FRANCISCO, May 29, 2025--(BUSINESS WIRE)--Rune Labs, the leader in precision medicine for Parkinson's disease (PD), today announced the launch of a clinical program with Parkinson's Foundation to accelerate the discovery of genetic and digital biomarkers for PD that can be used to provide breakthroughs in diagnostics, therapy development, and clinical trial design. By mapping gene variants to real-world symptom and medication data, the study will reveal wearable-based biomarker correlations in Parkinson's patients. The study, supported through the Global Parkinson's Genetics Program (GP2), will leverage Rune Labs' StrivePD AI-driven software and PD GENEration, the flagship genetic testing and counseling initiative from the Parkinson's Foundation. The GP2 program, one of three Aligning Science Across Parkinson's (ASAP) initiative-funded programs implemented by The Michael J. Fox Foundation, aims to improve understanding of the genetic architecture of PD by integrating ancestrally diverse populations to address a large gap in scientists' knowledge about the disease. Led by Dr. Andrew B. Singleton and Dr. Cornelis Blauwendraat, GP2's partnership with the Parkinson's Foundation will further increase the ancestral diversity of global PD genetic data. Despite a growing global patient population—expected to exceed 25 million by 2050—people with Parkinson's still need advances in diagnostics and treatments, despite progress over the past two decades. The study is intended to help address this by identifying biological and digital signatures of the disease that can support earlier diagnosis, more precise patient stratification for clinical trials, and the development of better-targeted treatment strategies. Leveraging StrivePD, participants will use an iPhone and Apple Watch to track motor symptoms passively, including tremor and dyskinesia, along with self-reported activities like mood and medications, while completing remote surveys and rating scales on their health and Parkinson's symptoms. Through PD GENEration, participants will undergo genetic testing and counseling by providing a blood sample that will be used to test for clinically validated PD-related genetic variants. The study may help participants determine eligibility for genetically based clinical studies. "We believe that there is significant potential to advance Parkinson's research by combining genetic insights with real-world data derived from AI-driven platforms like StrivePD to define disease subtypes. As trials become more precise, we can leverage data from this new study to reduce the noise, match patients to the right interventions, and generate stronger evidence to support the development of much-needed personalized treatments. If you carry a gene mutation, you shouldn't be treated like every other patient. This study could move us from 'average-patient' dosing to genome-matched therapy recommendations," said Brian Pepin, CEO of Rune Labs. StrivePD closes the gap in Parkinson's care caused by infrequent specialist visits and unpredictable symptoms. Through AI-driven monitoring, the software care ecosystem combines Apple Watch data with the StrivePD app to track FDA-cleared metrics like tremor and dyskinesia, plus self-reported daily routines, to deliver real-time insights and proactive treatment guidance. By providing insights into symptoms at all hours of the day, StrivePD helps patients manage symptoms between visits, improve medication adherence, and avoid unnecessary ER trips, allowing them to take control of their disease and ease the pressure on the healthcare system. Using AI and extensive real-world patient data, StrivePD is also changing how neurological clinical trials are designed, helping improve predictive accuracy and reducing trial failures. PD GENEration from the Parkinson's Foundation is an international research initiative offering genetic testing and counseling at no cost to individuals diagnosed with PD. Since its inception in 2019, PD GENEration has enrolled over 24,000 people living with PD (PwP) across North, Central, and South America, the Caribbean, and Israel. PD GENEration's mission is to help PwP better understand their genetic link to PD and manage their PD treatment and care, contribute to the scientific understanding of PD now and into the future, and accelerate enrollment into clinical trials by empowering PwP and clinicians around the importance of genetics. "We created PD GENEration to empower those with Parkinson's and their families to know more about their disease, accelerate clinical trials [that may one day halt Parkinson's], and drive forward research into the complex genetic factors that contribute to Parkinson's severity, progression, and treatment response," said James Beck, PhD and Chief Scientific Officer of the Parkinson's Foundation. "This new study with Rune Labs brings in powerful digital insights that can help us decode Parkinson's even further and speed up the path toward more effective treatments, and one day, a cure. Together, we can make better lives for those living with PD." Initial genotype-response findings are expected in 2026, with anonymized results made available to researchers through the GP2 data repository to accelerate future studies. About Rune Labs Rune Labs is an AI-led data analytics company for precision neurology, supporting care delivery and therapy development. StrivePD is the company's care delivery ecosystem for Parkinson's disease, enabling patients and their clinicians to better manage the disease by providing access to summarized objective and subjective data to improve treatment decisions, enhance disease management and connect patients to clinical trials. For therapeutics development, biopharma and medical device companies leverage Rune's technology, network of engaged clinicians and patients, and large longitudinal real-world datasets to expedite development programs. The company has received financial backing from leading investors such as Nexus NeuroTech, Eclipse Ventures, DigiTx, TruVenturo and Moment Ventures. For more information, please visit and About Parkinson's Foundation The Parkinson's Foundation makes life better for people with Parkinson's disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson's community. Since 1957, the Parkinson's Foundation has invested more than $474 million in Parkinson's research and clinical care. Connect with us on Facebook, X, Instagram or call 1-800-4PD-INFO (1-800-473-4636). About the Global Parkinson's Genetics Program The Global Parkinson's Genetics Program (GP2) is an ambitious program focused on improving our understanding of the genetic architecture of the PD spectrum in a global context. This work will help address the most pressing needs of the global PD community, accelerating development and deployment of better PD therapies. GP2 is made up of member organizations around the world that are coming together to create a global research community. GP2 is funded by the Aligning Science Across Parkinson's (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson's Disease Research. About Parkinson's Disease Affecting an estimated one million Americans, Parkinson's disease is the second-most common neurodegenerative disease after Alzheimer's and is the 14th-leading cause of death in the U.S. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for Parkinson's and nearly 90,000 new cases are diagnosed each year in the U.S. View source version on Contacts Media Contact Consort Partners for Rune Labsrunelabs@ Sign in to access your portfolio
